|
AMLX Amylyx Pharmaceuticals Inc 1658551 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$-41,284,000.00 |
| Balance Sheet |
|
Current Assets
|
$285,024,000.00 |
|
Assets
|
$293,603,000.00 |
|
Current Liabilities
|
$15,966,000.00 |
|
Liabilities
|
$20,442,000.00 |
|
Equity
|
$273,161,000.00 |
|
Shares Out
|
111026477.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-36,882,000.00 |
|
Investing Cash Flow
|
$36,262,000.00 |
| Market Analysis |
Market Cap
|
$2,303,799,397.75 |
|
Price
|
$19.65 |
|
BVPS
|
2.46 |
|
PB
|
8.44 |
|
EPS
|
-0.37 |
|
FCF
|
$-71,982,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:23 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:19 |
|
| Apr |
May |
Jun |
| 2026-03-03 |
-0.30 |
|
|
2026-05-07 |
-0.37 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-07 |
-0.46 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-06 |
-0.37 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view AMLX documents filed with the SEC.
AMLX Filings
Clear
